ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Aptus Pharma got BSE in-principle approval for a preferential issue of 15,99,270 shares at a minimum Rs. 280 each. The issue is worth about Rs. 44.78 Crore.
H1 FY27 revenue ₹48.92 Cr, EBITDA ₹7.68 Cr (15.7% margin), PAT ₹5.07 Cr; revenue exceeds full FY26 (₹46.57 Cr). Trading-heavy model with rising receivables and negative operating cash flow.
Aptus Pharma Ltd reported revenue from operations of ₹48.9 Cr (+239.6% YoY) and net profit of ₹5.1 Cr (+200.0% YoY) for H1 FY27.
Aptus Pharma Limited submitted the Regulation 74(5) compliance certificate for the quarter and half-year ended 30th September 2026, as received from its registrar.